CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...
Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage ...
Through genome editing using CRISPR/Cas9, researchers stably create euglena mutants that can produce wax esters with improved cold flow, making the esters suitable as feedstock for biofuels. News ...
Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to ...
Gene editing has enormous potential to help feed the world’s growing population, but it’s currently difficult, time-consuming ...
CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...
CHICAGO – A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results